A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Inclusion Criteria:

• Diagnosis of Crohn's disease (CD) for at least 3 months prior to baseline

• Confirmed diagnosis of moderate to severe CD as assessed by Crohn's disease activityindex (CDAI), stool frequency (SF), abdominal pain (AP) score and simple endoscopicscore for Crohn's disease (SES-CD)

• Demonstrated inadequate response, loss of response, or intolerance to at least onebiologic approved for the treatment of Crohn's disease

• If female and of childbearing potential, must meet the contraception andreproduction requirements

Exclusion Criteria:

• Complications of CD that may be anticipated to require surgery

• Currently has or is suspected to have an abscess. Recent cutaneous and perianalabscesses are not exclusionary if drained and adequately treated at least 3 weeksbefore baseline, or 8 weeks before baseline for intra-abdominal abscesses, providedthat there is no anticipated need for any further surgery

• Has had any kind of bowel resection within 24 weeks, or any other intra-abdominal orother major surgery within 12 weeks

• Has a draining (example, functioning) stoma or ostomy

• Currently has a malignancy or has a history of malignancy within 5 years beforescreening (with the exception of a nonmelanoma skin cancer or cervical carcinoma insitu that has been adequately treated with no evidence of recurrence for greaterthan or equal do (>=) 12 months before the first dose of study intervention)

• Has a history of, or ongoing, chronic or recurrent infectious disease, including butnot limited to, sinopulmonary infections, bronchiectasis, recurrent renal/urinarytract infections (example, pyelonephritis, cystitis), an open, draining, or infectedskin wound, or an ulcer